摘要
目的探讨乌司他丁与生长抑素联合用于急性胰腺炎患者的临床效果及对患者并发症的预防作用。方法随机选取2021年1月—2024年4月江苏省盱眙县人民医院收治的120例急性胰腺炎患者为研究对象,依据不同用药方案分为对照组和观察组,各60例。对照组连续7 d应用生长抑素治疗,观察组则连续7 d应用乌司他丁+生长抑素治疗。对比两组患者的临床治疗效果、生化相关指标、症状改善时间、住院时间及并发症发生情况,分析药物联用的临床价值。结果观察组临床治疗总有效率96.67%(58/60)高于对照组的83.33%(50/60),差异有统计学意义(χ^(2)=5.926,P<0.05);治疗后,两组肿瘤坏死因子-α、白细胞介素-6、C-反应蛋白以及血淀粉酶水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P均<0.05);观察组患者腹痛消失时间、腹胀缓解时间及住院时间均短于对照组,差异有统计学意义(P均<0.05);两组并发症总发生率对比,差异无统计学意义(P>0.05)。结论急性胰腺炎患者采用乌司他丁和生长抑素联合治疗,可提高整体治疗效果,对患者症状加以改善,调节机体生化指标,且不会因联用药物而出现诸多并发症,可维护患者用药安全性。
Objective To investigate the clinical effect of ulinastatin combined with somatostatin in patients with acute pancreatitis and its preventive effect on complications.Methods A total of 120 patients with acute pancreatitis admit⁃ted to Xuyi County People's Hospital of Jiangsu Province from January 2021 to April 2024 were randomly selected as the research objects.According to different medication regimens,they were divided into control group and observation group,with 60 cases in each group.The control group was treated with somatostatin for 7 consecutive days,while the observation group was treated with ulinastatin+somatostatin for 7 consecutive days.The clinical treatment effect,bio⁃chemical related indexes,symptom improvement time,hospitalization time and complications of the two groups were compared,and the clinical value of drug combination was analyzed.Results The total effective rate of clinical treat⁃ment in the observation group was 96.67%(58/60),which was higher than that in the control group 83.33%(50/60),the difference was statistically significant(χ^(2)=5.926,P<0.05);after treatment,the levels of tumor necrosis factor-α,interleukin-6,C-reactive protein and blood amylase in the two groups were lower than those before treatment,and the observation group was lower than the control group,the differences were statistically significant(all P<0.05).The dis⁃appearance time of abdominal pain,relief time of abdominal distension and hospitalization time in the observation group were shorter than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of complications between the two groups(P>0.05).Conclusion The combination of ulinastatin and somatostatin in patients with acute pancreatitis can improve the overall treatment effect,improve the symptoms of patients,regulate the body's biochemical indicators,and will not appear many complications due to the combination of drugs,which can maintain the safety of pati
作者
张永琪
ZHANG Yongqi(Department of Gastroenterology,Xuyi County People's Hospital,Xuyi,Jiangsu,211700,China)
出处
《中外医疗》
2024年第26期112-115,共4页
China & Foreign Medical Treatment
关键词
乌司他丁
生长抑素
急性胰腺炎
治疗效果
生化指标
并发症
Ulinastatin
Somatostatin
Acute pancreatitis
Therapeutic effect
Biochemical indicators
Complications
